Managing director in Berkeley Research Group's Healthcare Transactions and Strategy practice
Congress Unlikely to Codify Executive Order on Drug Pricing: John Barkett, MBA
Congress is unlikely to codify the recent executive order to lower drug pricing as other US officials negotiate new prices, John Barkett, MBA, of Berkeley Research Group, explains.
Effects of Executive Order Could Take Years to Appear: John Barkett, MBA
The immediate impact of the recent executive order aimed at lowering drug prices is likely low, as it may take until 2027 before actions detailed in the order can be enacted.
Legal Challenges Likely Following Drug Pricing Executive Order: John Barkett, MBA
The executive order that President Donald Trump signed to lower drug prices could come under legal challenges by the drug industry.
How Trump's New Drug Pricing EO Differs From Past Attempts: John Barkett, MBA
The executive order signed on May 12 has some differences from a previous executive order originally signed by the Trump administration in 2020.
New Executive Order Aims for Most-Favored Nation Pricing: John Barkett, MBA
The new executive order contains multiple provisions if pharmaceutical companies do not offer "most-favored nation" pricing on medication.